Paragon 28 Inc (7GQ.BE)
| Previous close | 9.05 |
| Open | 9.25 |
| Bid | 8.85 x N/A |
| Ask | 9.15 x N/A |
| Day's range | 9.25 - 9.25 |
| 52-week range | 7.60 - 17.40 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Paragon 28, Inc. (NYSE:FNA) has caught the attention of institutional investors who hold a sizeable 36% stake
Key Insights Institutions' substantial holdings in Paragon 28 implies that they have significant influence over the...
- Business Wire
Paragon 28 Announces CFO Transition, Provides Preliminary Unaudited Net Revenue for First Quarter 2024, and Reaffirms Net Revenue Guidance for Fiscal Year 2024
ENGLEWOOD, Colo., April 04, 2024--Paragon 28, Inc. (NYSE: FNA), ("Paragon 28" or "the Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Stephen Deitsch, Chief Financial Officer ("CFO"), has notified the Company of his intent to pursue an opportunity with OrganOx Limited, a commercial stage UK-based medical device company focused on therapeutic applications of isolated organ perfusion. Mr. Deitsch will depart from the Com
ZacksParagon 28 (FNA) Expands Syndesmotic Repair Line With New Launch
The dynamic functionality of Paragon 28's (FNA) Grappler R3INFORCE System sets it apart from traditional static repair systems, offering a more physiological and anatomical reconstruction option.
